Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.
Home P, Blonde L, Kalra S, Ji L, Guyot P, Brulle-Wohlhueter C, Murray E, Shah R, Sayre T, Shaunik A. Home P, et al. Among authors: shaunik a. Diabetes Obes Metab. 2020 Nov;22(11):2179-2188. doi: 10.1111/dom.14148. Epub 2020 Sep 3. Diabetes Obes Metab. 2020. PMID: 32700442
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
Home PD, Aroda VR, Blonde L, Guyot P, Shaunik A, Fazeli MS, Goswami H, Kalra S, Pourrahmat MM. Home PD, et al. Among authors: shaunik a. Diabetes Obes Metab. 2020 Nov;22(11):2170-2178. doi: 10.1111/dom.14136. Epub 2020 Jul 26. Diabetes Obes Metab. 2020. PMID: 32627297
Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.
Rayner CK, Wu T, Aroda VR, Whittington C, Kanters S, Guyot P, Shaunik A, Horowitz M. Rayner CK, et al. Among authors: shaunik a. Diabetes Obes Metab. 2021 Jan;23(1):136-146. doi: 10.1111/dom.14202. Epub 2020 Oct 22. Diabetes Obes Metab. 2021. PMID: 32991041 Free PMC article.
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.
McCrimmon RJ, Al Sifri S, Emral R, Mohan V, Sauque-Reyna L, Trescolí C, Lalic N, Alvarez A, Demil N, Coudert M, Shaunik A, Bonnemaire M, Rosenstock J; SoliMix Trial investigators. McCrimmon RJ, et al. Among authors: shaunik a. Diabetes Obes Metab. 2021 Jun;23(6):1221-1231. doi: 10.1111/dom.14354. Epub 2021 Apr 29. Diabetes Obes Metab. 2021. PMID: 33606908 Clinical Trial.
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline.
Pratley RE, Jacob S, Baek S, Trautmann ME, Hompesch M, Han O, Stewart J, Sorli CH, Shaunik A, Yoon KH. Pratley RE, et al. Among authors: shaunik a. BMJ Open Diabetes Res Care. 2022 Jan;10(1):e002207. doi: 10.1136/bmjdrc-2021-002207. BMJ Open Diabetes Res Care. 2022. PMID: 35042751 Free PMC article. Clinical Trial.
Evaluating glycaemic control in patients poorly controlled on oral antidiabetic drugs in real-world setting: Results from assessing the Appropriate Timing of Type 2 diAbetes INtensification (ATTAIN).
Jude EB, O'Leary C, Myland M, Nixon M, Gooch N, Shaunik A, Lew E. Jude EB, et al. Among authors: shaunik a. Endocrinol Diabetes Metab. 2019 Sep 29;3(1):e00094. doi: 10.1002/edm2.94. eCollection 2020 Jan. Endocrinol Diabetes Metab. 2019. PMID: 31922021 Free PMC article.
48 results